Pivotal Experiment Fund2022-08-22T14:31:31-04:00
Banner Building a Biotech Venture

The Pivotal Experiment Fund (PEF) is a strategic and competitive program intended to advance translation of Medicine by Design’s team projects portfolio. The PEF aims to build a robust, pre-clinical pipeline of regenerative medicine-based therapies, enabling technologies and ventures that have strong potential for clinical, socio-economic and/or commercial impact. Medicine by Design will invest up to $3 million in the PEF.

On This Page

About the Pivotal Experiment Fund

The PEF will bridge a critical gap within the innovation ecosystem by supporting early-stage regenerative medicine research discoveries to a point where follow-on investment from third parties is attractive. A pivotal experiment is one that enables a “go/no go” decision on the merits of a product concept based on outcomes that drive a value inflection in the development plan. The PEF is a strategic and competitive program intended to advance translation of select Medicine by Design team (Cycle 2) projects.

The PEF will

  • Provide project funding of up to $250,000 over 6 to 12 months. In exceptional cases, consideration may be given to a larger investment, subject to discussions with Medicine by Design during the proposal development process.
  • Support the generation of pivotal proof-of-concept and/or validation data, enabling the first steps towards demonstrating therapeutic potential and/or technological utility.
  • Support projects that are defined by clear, milestone-driven (clear go/no go) decision points over a 6 to 12 months period.
  • Encourage projects that leverage co-investment from ecosystem partners and programs (e.g. Connaught Innovation Award, UHN Innovation Acceleration Fund, CCRM, TIAP/LAB150, industry partners, etc.).

Project activities can include but are not limited to:

  • Generation of preclinical, pivotal in vivo efficacy and/or proof-of-concept data.
  • Demonstration of a technology for a regenerative medicine application.
  • Critical, pivotal experiments to support the early stages of target validation.
  • Drug screening on a validated target.
  • Demonstrating feasibility of cell manufacturing scale-up.

Investment Review Committee

Bharat Srinivasa

Co-Founder and Principal, Amplitude Ventures
Learn more

Glenn Maclean

Director, Technology and Venture Development, CCRM

Jacques Sayegh

CEO and Managing Partner, Samuel Capital Partners
Learn more

Jamie Stiff

Managing Director, Genesys Capital
Learn more

Matthew Mistry

Market and Equity Analyst, CCRM Enterprises Inc.
Learn more

Parimal Nathwani

CEO, Toronto Innovation Acceleration Partners (TIAP)
Learn more

How to apply

Please note: Applications are currently not being accepted, as the latest round of funding has been awarded. Dates for future funding rounds are TBD. Contact awards.mbd@utoronto.ca with any questions.

Application documents can be found at the links below:

Go to Top